Boehringer Bids To Go Beyond Slowing IPF
Promising Phase II Data In Lung Disease With High Mortality
The family-owned German group is the market leader in idiopathic pulmonary fibrosis with Ofev but the big-selling drug has significant side effects and only slows, but does not stop, the progression of the disease. It is hoping that the Phase III-ready compound BI 1015550 will offer a significant improvement.
